Daniel Campbell

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Margaret Rosenfeld, Claire Wainwright, Mark Higgins et al. · The Lancet Respiratory Medicine · 2018 · 270 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +14

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries

Nataliya Volkova, Kristin A. Moy, Jennifer Evans et al. · Journal of Cystic Fibrosis · 2019 · 255 citations

Medicine, Internal Medicine, Pharmacotherapy +14

Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial

Jane C. Davies, Claire Wainwright, Gregory S. Sawicki et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 101 citations · Full text

Pharmacy, Pediatrics, Pharmacology +17

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation

Jane C. Davies, Isabelle Sermet‐Gaudelus, Lutz Naehrlich et al. · Journal of Cystic Fibrosis · 2020 · 68 citations

Pharmacy, Genetics, Pharmacotherapy +16

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Patrick A. Flume, Reta Fischer Biner, D.G. Downey et al. · The Lancet Respiratory Medicine · 2021 · 51 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13